ECS Botanics Holdings Ltd

ECS

ECS Botanics Holdings Ltd. manufactures, supplies and retails cannabis products. The firm utilizes progressive and cultivation methodologies to produce medicine in a sustainable way, adopting regenerative and organic horticultural practices and renewable energy sources. The firm operates through two segments: ECS Botanics Pty Ltd (Botanics) and ECS Botanics MC Pty Ltd and Flowerday Farms Pty Ltd. Botanics is engaged in the sale of food and wellness products. ECS Botanics MC Pty Ltd and Flowerday Farms Pty Ltd are engaged in the sale of medicinal cannabis plant related products. The company specializes in cultivating cannabis, which after drying and curing, is supplied as a trimmed flower for inhalation, or extracted into resin for further formulation or manufacturing. The company cultivates a range of strains for extraction and inhalation. The company also formulates a range of off the shelf and bespoke formulations to suite needs.

Syntara Limited

SNT

Syntara Ltd. is a pharmaceutical research company, which engages in the development and commercialization of healthcare products for fibrotic and inflammatory diseases. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. The firm is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The firm is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.

Cann Group Limited

CAN

Cann Group Ltd. engages in the cultivation of medicinal cannabis and further processing into manufactured medicinal cannabis products. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-05-04. The principal activities of the Company include the cultivation of medicinal cannabis for both medicinal and research purposes pursuant to the licenses and permits issued to the group, the development and manufacture (via third party arrangements) of finished product formulations, and the pursuit and execution of various supply agreements with third parties. The company operates through cultivation of the medicinal cannabis segment. The firm supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. The company also owns Satipharm and its patent-protected capsule technology. The firm's research, cultivation, and good manufacturing practices (GMP) manufacturing facilities are in Melbourne, and a cultivation and GMP manufacturing facility is near Mildura, Victoria.

Magnis Energy Technologies Ltd

MNS

Magnis Energy Technologies Ltd. is an integrated lithium-ion battery technology and materials company, which engages in the business of exploring, developing, and mining natural flake graphite. The company is headquartered in Sydney, New South Wales and currently employs 9 full-time employees. The company went IPO on 2005-10-25. Its subsidiary, Imperium3 New York Inc. (iM3NY), operates the Lithium-ion battery plant in Endicott, New York. iM3NY has commenced commercial production of Li ion cells and accelerating its ramp-up plans to produce 15,000 cells/day up to an annual production rate of 1.8 gigawatt hours with several binding offtakes already secured. Charge CCCV’s (C4V’s) proprietary Li-ion battery technology and discoveries are known for extending battery life, greater safety and charge performance. C4V’s also provides value chain solutions for Li ion battery manufacturing through cell design and engineering, cell fabrication process, qualification of raw materials supply chain and cell fabrication equipment supplier, blueprint of plants and engaging with engineering, procurement and construction (EPC) contractors.

Actinogen Medical Limited

ACW

Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The firm is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. The company has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The firm conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamem’s therapeutic potential.